Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186
Clinical Trials01:16

Clinical Trials

6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

762
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
762
Hazard Ratio01:12

Hazard Ratio

121
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
121

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NHLBI Workshop Panel Discussion: Summary of the Workshop.

Statistics in medicine·2026
Same author

Sequential Event Rate Monitoring.

Statistics in medicine·2026
Same author

Myocardial Entropy and Risk Predictors in Hypertrophic Cardiomyopathy: An Analysis From the NHLBI HCM Registry.

Circulation. Cardiovascular imaging·2025
Same author

Liquefied Petroleum Gas or Biomass for Cooking and Effects on Blood Pressure: Results from the Household Air Pollution Intervention Network (HAPIN) Trial.

medRxiv : the preprint server for health sciences·2025
Same author

Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Testing and Estimation of Treatment Effects in Clinical Trials for Terminal and Nonterminal Events Subject to Competing Risks.

Statistics in medicine·2025

Related Experiment Video

Updated: Jul 2, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Use of win time for ordered composite endpoints in clinical trials.

James F Troendle1, Eric S Leifer1, Song Yang1

  • 1Office of Biostatistics Research, Division of Intramural Research of the National Heart, Lung, and Blood Institute, NIH/DHHS, Bethesda, Maryland, USA.

Statistics in Medicine
|February 28, 2024
PubMed
Summary

New clinical trial methods, including variants of the win ratio, better capture overall treatment benefit from a patient

Keywords:
bootstraphazardpairwise comparisonwin ratiowin time

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K

Related Experiment Videos

Last Updated: Jul 2, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Survival Analysis

Background:

  • Clinical trials often assess treatment benefit by analyzing time-to-first-event data.
  • Existing methods like the ordinary win ratio may not fully capture the patient's overall treatment experience.
  • There is a need for statistical approaches that provide a more comprehensive assessment of treatment benefit and harm.

Purpose of the Study:

  • To introduce and evaluate novel variants of the win ratio for clinical trials measuring multiple clinical events.
  • To develop methods that better reflect the patient's perspective on overall treatment benefit and harm.
  • To compare the performance of these new methods against existing approaches like the composite event and ordinary win ratio.

Main Methods:

  • Development of several new win ratio variants incorporating time spent in clinical states.
  • One variant prioritizes death while accounting for time in other states.
  • Other variants include average pairwise win time, expected win times (EWTs) against a reference distribution, and methods using estimated clinical state distributions.
  • A combination testing approach is proposed for robust power across various scenarios.
  • Methods were compared using simulations and re-analysis of a heart failure trial.

Main Results:

  • Simulations indicate that variants based on expected win times (EWTs) or estimated clinical state distributions offer substantially higher power when treatment benefit on death is significant.
  • These novel methods demonstrated superior performance compared to pairwise comparison or composite event methods in specific scenarios.
  • The methods provide a more nuanced evaluation of treatment effects, aligning better with patient-centered outcomes.

Conclusions:

  • The proposed win ratio variants and combination testing approach offer improved statistical power and a more patient-relevant assessment of treatment benefit in clinical trials.
  • Methods incorporating time spent in clinical states, particularly EWTs and estimated state distributions, are effective for detecting treatment benefits, especially concerning mortality.
  • These advanced statistical tools enhance the interpretation of clinical trial results for guiding therapeutic decisions.